ClinicalTrials.gg
CompletedNCT02350634Updated Jun 10, 2025Results posted

18F-AV-1451 High Resolution Autopsy Study

A Phase 1 interventional study of Flortaucipir F18 in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 60 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
60 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
21st of 22
3 · median 70
Started
2016
with 2 others
Phase 1
10 of 22
2 open now
Registered
7th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 21st largest by enrollment, is one of 3 that started in 2016, is one of 10 in phase 1, and was the 7th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

The study is designed to examine the relationship between imaging results detected on a 18F-AV-1451 PET scan and pathology found at autopsy within six months of imaging.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Projected ≤ 6 months

Exclusion criteria

Exclusion Criteria:

  • Primary brain tumor, known to the brain, central nervous system lymphoma
  • Major, focal structural brain lesion
  • Aggressively being treated with life sustaining measures
  • infectious disease
  • History of risk factors for Torsades de Pointes or are currently taking medication known to cause
  • Have received or participated in a trial with medications in the past 30 days
  • Females of who are pregnant or not using adequate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Autopsy Cohort

    End-of-life subjects (life expectancy \< 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of flortaucipir F18.

    Drug: Flortaucipir F18

Interventions

  • Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of flortaucipir.

    Also known as: [F-18]T807, 18F-AV-1451

06

What researchers measure

Primary outcomes

  1. Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of whole cortical global quantitation of the PET scan from 82 FreeSurfer-defined regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  2. Relationship of Flortaucipir Scan and Pathology - Frontal Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of frontal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  3. Relationship of Flortaucipir Scan and Pathology - Parietal Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of parietal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  4. Relationship of Flortaucipir Scan and Pathology - Cingulate Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of cingulate composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  5. Relationship of Flortaucipir Scan and Pathology - Temporal Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of temporal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  6. Relationship of Flortaucipir Scan and Pathology - Occipital Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of occipital composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

  7. Relationship of Flortaucipir Scan and Pathology - Limbic Composite Region

    Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of limbic composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

    Time frame: autopsy within 6 months of scan

07

Results

Posted Jun 10, 2025
Limitations and caveats
The original intent of the protocol was to assess relationships between in vivo flortaucipir PET signal and tau pathology at a higher resolution than the Free Surfer ROIs, such as voxel-wise. Higher resolution could potentially offer more precise insights into tracer distribution patterns. However, the analysis was constrained by challenges in acquiring a complete set of pathology images from collaborators and unanticipated technical challenges in image processing.

Participant flow

Enrollment was opened in June 2015 and closed in May 2018. First patient enrolled in November 2016 and last enrolled patient completed the study procedures in June 2017. Study enrolled end-of-life subjects (life expectancy less than 6 months) at medical centers in the US who consented to a flortaucipir PET scan and to brain donation at autopsy.

Participant flow — Overall Study
MilestoneAll Enrolled Cohort
Started3
Completed2
Not completed1
Withdrew: Subject survived greater than 6 months following dosing1

Outcome measures

PrimaryRelationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of whole cortical global quantitation of the PET scan from 82 FreeSurfer-defined regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region0.429
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = <0.001 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.429
PrimaryRelationship of Flortaucipir Scan and Pathology - Frontal Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of frontal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Frontal Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Frontal Composite Region0.681
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = <0.001 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.681
PrimaryRelationship of Flortaucipir Scan and Pathology - Parietal Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of parietal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Parietal Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Parietal Composite Region0.644
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = 0.00278 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.644
PrimaryRelationship of Flortaucipir Scan and Pathology - Cingulate Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of cingulate composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Cingulate Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Cingulate Composite Region0.437
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = 0.12 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.437
PrimaryRelationship of Flortaucipir Scan and Pathology - Temporal Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of temporal composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Temporal Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Temporal Composite Region0.324
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = 0.0712 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.324
PrimaryRelationship of Flortaucipir Scan and Pathology - Occipital Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of occipital composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Occipital Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Occipital Composite Region0.564
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = 0.0958 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: 0.564
PrimaryRelationship of Flortaucipir Scan and Pathology - Limbic Composite Region

Correlation between flortaucipir standard uptake value ratio (SUVr) and neuropathology at autopsy. SUVr measurements for the analysis consisted of limbic composite region quantitation of the PET scan regions of interest (ROIs). Values were normalized to the brainstem to obtain the SUVr. Neuropathology was measured by immunohistology using AT8 antibody. Spearman correlation coefficient was calculated. Spearman correlation coefficients range from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.

Time frame:
autopsy within 6 months of scan
Reported as:
Number · Correlation coefficient
Relationship of Flortaucipir Scan and Pathology - Limbic Composite Region
Correlation coefficientAutopsy Cohort
Relationship of Flortaucipir Scan and Pathology - Limbic Composite Region-0.189
Statistical analysis
  • Autopsy Cohort · Spearman's Rank Order Correlation test · p = 0.558 (A two-sided correlation test (rho ≠ 0) was performed with a significance level of alpha = 0.05 to assess a significant correlation.) · Correlation coefficient: -0.189

Adverse events

Collected over Up to a total of 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Analysis Cohort2/3 (66.7%)0/3 (0%)0/3 (0%)

Baseline characteristics

All subjects consenting to flortaucipir PET and brain donation at autopsy

Age, Continuous
Age, Continuous(years)All Enrolled Cohort
Mean76.00 ± 11.533
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Cohort
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Enrolled Cohort
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Enrolled Cohort
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
Mini Mental Status Exam (MMSE) Score
Mini Mental Status Exam (MMSE) Score(units on a scale)All Enrolled Cohort
Mean14.50 ± 20.5061
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) Score
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) Score(units on a scale)All Enrolled Cohort
Mean4.75 ± 0.4330
08

Study locations

2 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • University of California, San Francisco
    San Francisco, California 94121, United States
09

References and documents

Publications

  • Ushizima D, Chen Y, Alegro M, Ovando D, Eser R, Lee W, Poon K, Shankar A, Kantamneni N, Satrawada S, Junior EA, Heinsen H, Tosun D, Grinberg LT. Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation. Neuroimage. 2022 Mar;248:118790. doi: 10.1016/j.neuroimage.2021.118790. Epub 2021 Dec 20. PubMed 34933123 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jun 2017, 6 months.

Results were first posted in Jun 2025, 7 years 11 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 6 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2015
First posted
Jan 30, 2015
StartActual
Nov 26, 2016
Primary completionActual
Jun 16, 2017
CompletionActual
Jun 16, 2017
Results first posted
Jun 10, 2025
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02350634
Responsible party
Sponsor
First posted
Jan 30, 2015
Start date
Nov 26, 2016
Primary completion
Jun 16, 2017
Completion
Jun 16, 2017
Results posted
Jun 10, 2025
Last update
Jun 10, 2025

Study contacts

Medical Director
study director · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion